Sex differences in cancer risk and outcomes after kidney transplantation.


Journal

Transplantation reviews (Orlando, Fla.)
ISSN: 1557-9816
Titre abrégé: Transplant Rev (Orlando)
Pays: United States
ID NLM: 8804364

Informations de publication

Date de publication:
07 2021
Historique:
received: 21 01 2021
revised: 27 04 2021
accepted: 28 04 2021
pubmed: 22 5 2021
medline: 29 10 2021
entrez: 21 5 2021
Statut: ppublish

Résumé

Kidney transplant recipients (KTRs) experience a two- to four-fold increased risk of developing and dying from cancer compared with the general population. High cancer risk results from the interaction of both modifiable and non-modifiable factors. This mapping review explores the impact of sex disparity on cancer's increased incidence and mortality after kidney transplantation (KT). In terms of age, population-based studies indicate that younger recipients of both sexes experience a higher risk of cancer, but this is more pronounced in young women. On the contrary, older men are more likely to be diagnosed with cancer, although their increased risk is not statistically significant compared with the general population. Regarding cancer type, studies show an increased risk of Kaposi sarcoma, gynecologic and lung cancer in women, and bladder and kidney cancer in men. Immune-related cancers such as pos-transplant lymphoproliferative disorders and melanoma are increased in both sexes. Mortality also shows differences between sexes. Although cancer is the second cause of death in both male and female KTRs, studies show higher overall mortality in men and elderly recipients. However, the relative risk of cancer mortality compared with the general population is higher at a younger age, with disparate results regarding sex. Female KTRs appear to die at a younger age than males when compared with the general population. Differences in cancer rates by sex after renal transplantation need further studies. A better understanding of sex-specific differences in cancer epidemiology after KT could help nephrologists to better address pre-transplant counseling, to establish early surveillance programs, and to plan modifiable risk factors such as immunosuppression.

Identifiants

pubmed: 34020178
pii: S0955-470X(21)00031-8
doi: 10.1016/j.trre.2021.100625
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

100625

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Anna Buxeda (A)

Department of Nephrology, Hospital del Mar, Barcelona, Spain. Electronic address: abuxeda@psmar.cat.

Dolores Redondo-Pachón (D)

Department of Nephrology, Hospital del Mar, Barcelona, Spain.

María José Pérez-Sáez (MJ)

Department of Nephrology, Hospital del Mar, Barcelona, Spain.

Marta Crespo (M)

Department of Nephrology, Hospital del Mar, Barcelona, Spain.

Julio Pascual (J)

Department of Nephrology, Hospital del Mar, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH